Sling gets $123M for Phase 3 trial of ex-Astellas drug in thyroid eye disease

Summary

Sling Therapeutics secured $123 million in funding to advance a Phase 3 trial of a repurposed Astellas cancer drug for thyroid eye disease. The financing underscores growing investor interest in the thyroid eye disease space.